Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Monika Haubitz, PhD, Elisabeth Oppliger Leibundgut, PharmD, Ingrid Helsen, Dania Hiltbrunner, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Röth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD

Blood (2016) 128 (22): 1938.

https://doi.org/10.1182/blood.V128.22.1938.1938

Published: 2016

Journal Articles

The JAK2 V617F Stem Cell Burden Is Mosaic, Dynamic and Correlates with Clinical Disease Burden in the MPN: An Exploitable Target

Alison R Moliterno, MD, Donna Marie Williams, PhD, Jonathan M. Gerber, MD, Michael A McDevitt, MD PhD, Ophelia Rogers, Jerry L. Spivak, MD

Blood (2015) 126 (23): 4090.

https://doi.org/10.1182/blood.V126.23.4090.4090

Published: 2015

Journal Articles

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Elisabeth Oppliger Leibundgut, PharmD, Monika Haubitz, PhD, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Roeth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD

Blood (2015) 126 (23): 57.

https://doi.org/10.1182/blood.V126.23.57.57

Published: 2015

Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

Blood (2015) 126 (23): 1361.

https://doi.org/10.1182/blood.V126.23.1361.1361

Published: 2015

Journal Articles

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Blood (2015) 125 (19): 3024–3031.

https://doi.org/10.1182/blood-2015-01-623991

Published: 2015

Includes: Supplemental data

Journal Articles

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Blood (2014) 124 (25): 3817–3827.

https://doi.org/10.1182/blood-2014-07-587477

Published: 2014

Includes: Supplemental data

Journal Articles

Essential Thrombocytosis: Redefinition in the Genomic Era

Donna M. Williams, PhD, Michael A McDevitt, MD PhD, Brady L Stein, MDMHS, Ophelia Rogers, Michael B. Streiff, MD, David Neal, Sophie Lanzkron, MD MHS, Linda M. S. Resar, MD, Christine O'Keefe, PhD, Jaroslaw P. Maciejewski, MD PhD, Jerry L. Spivak, MD, Alison R. Moliterno, MD

Blood (2014) 124 (21): 3205.

https://doi.org/10.1182/blood.V124.21.3205.3205

Published: 2014

Journal Articles

Epigenetic Silencing of BRCA1 Is Linked to Homologous Recombination Repair Defects and Elevated Mir-155 Expression in Myeloid Neoplasms

Weijie Poh, BS, Alison R Moliterno, MD, Keith W. Pratz, MD, Ivana Gojo, MD, Michael A McDevitt, MD PhD, James G. Herman, MD

Blood (2014) 124 (21): 3525.

https://doi.org/10.1182/blood.V124.21.3525.3525

Published: 2014

Journal Articles

Monitoring of Calr Allele Burden in Patients with Essential Thrombocythemia Treated with Imetelstat, a Telomerase Inhibitor, Reveals Rapid and Substantial Molecular Responses

Gabriela M. Baerlocher, MD, Monika Haubitz, PhD, Oliver G. Ottmann, MD, Olatoyosi Odenike, MBBS, Alexander Roeth, MD, Michael A McDevitt, MD PhD, Ted Shih, Bart Burington, Dianne Morfeld, Neeru Batra, BS, David Snyder, MD, Elisabeth Oppliger Leibundgut, PharmD

Blood (2014) 124 (21): 408.

https://doi.org/10.1182/blood.V124.21.408.408

Published: 2014

Journal Articles

Single Cell Analysis Of JAK2 V617F Positive MPN Stem/Progenitor Cells In Chronic Phase and Leukemic Transformation

Jonathan M. Gerber, MD, Donna M. Williams, PhD, Ophelia Rogers, Sarah Morse, Hao Zhang, Michael A McDevitt, MD, PhD, Richard J. Jones, Jerry L. Spivak, MD, Alison R. Moliterno, MD

Blood (2013) 122 (21): 1609.

https://doi.org/10.1182/blood.V122.21.1609.1609

Published: 2013

Journal Articles

Burst-Forming Unit-Erythroid Assays (BFU-E) Can Help Distinguish Cellular Bone Marrow Failure Disorders

Amy E. DeZern, MD, MHS, Michael A McDevitt, MD, Richard J. Jones, Robert A. Brodsky, MD

Blood (2012) 120 (21): 3475.

https://doi.org/10.1182/blood.V120.21.3475.3475

Published: 2012

Journal Articles

Polycythemia Vera: Redefinition in the Genomic Era

Alison R. Moliterno, MD, Donna M. Williams, PhD, Michael A McDevitt, MD, PhD, Brady L Stein, MD, Jonathan M. Gerber, MD, Ophelia Rogers, Michael B. Streiff, MD, Sophie Lanzkron, M.D., Linda Resar, M.D., Christine O'Keefe, PhD, Jaroslaw P. Maciejewski, MD, PhD, Jerry L. Spivak, MD

Blood (2012) 120 (21): 1754.

https://doi.org/10.1182/blood.V120.21.1754.1754

Published: 2012

Journal Articles

Somatic Mutations in Schinzel-Giedion Syndrome Gene SETBP1 Determine Progression in Myeloid Malignancies

Blood (2012) 120 (21): 2.

https://doi.org/10.1182/blood.V120.21.2.2

Published: 2012

Journal Articles

Pathway Analysis of Molecular Mutations Can Modify Morphologic, Cytogenetic and Prognostic Risk Stratification Schemes in Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN), and Secondary Acute Myeloid Leukemia (AML)

Edy Hasrouni, Valeria Visconte, PhD, Ali Tabarroki, MD, Heesun J. Rogers, MD, PhD, Fabiola Traina, MD, PhD, Anna Jankowska, MSC, Yang Liu, Betty K. Hamilton, MD, Manoj Bupathi, MD, Hideki Makishima, MD, PhD, Andres Jerez, MD, PhD, Edward A. Copelan, MD, Anjali Advani, MD, Michael A McDevitt, MD, PhD, Matt Kalaycio, MD, Yogen Saunthararajah, MD, Mikkael A. Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, PhD, Ramon V. Tiu, MD

Blood (2012) 120 (21): 3791.

https://doi.org/10.1182/blood.V120.21.3791.3791

Published: 2012

Journal Articles

Novel Recurrent Mutations in the Ras -Like GTP-Binding Gene Rit1 in Myeloid Malignancies

Inées Góomez-Seguíi, MD., Hideki Makishima, MD, PhD, Andres Jerez, MD, PhD, Kenichi Yoshida, MD, Bartlomiej P Przychodzen, Satoru Miyano, PhD, Yuichi Shiraishi, Holleh D Husseinzadeh, MD, Edward P Evans, Kathryn M Guinta, Naoko Hosono, MD., PhD., Michael A McDevitt, MD, PhD, Alison R. Moliterno, MD, Mikkael A. Sekeres, MD, MS, Seishi Ogawa, MD, PhD, Jaroslaw P. Maciejewski, MD, PhD

Blood (2012) 120 (21): 558.

https://doi.org/10.1182/blood.V120.21.558.558

Published: 2012

Journal Articles

Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis

Blood (2012) 119 (25): 6109–6117.

https://doi.org/10.1182/blood-2011-12-397620

Published: 2012

Includes: Supplemental data

Journal Articles

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Blood (2012) 119 (1): 55–63.

https://doi.org/10.1182/blood-2011-08-370825

Published: 2012

Includes: Supplemental data

Journal Articles

Final Results From a Phase II Trial of Triapine® Plus Fludarabine for Adults with Aggressive Myeloproliferative Disorders

Michael A McDevitt, MD, PhD, Robert L Dilley, Keith W. Pratz, MD, B. Douglas Smith, MD, Alison R. Moliterno, MD, Yun Yen, MD, PhD, Lisa Malick, RN, Steven D. Gore, MD, Richard J. Jones, Jaroslaw P. Maciejewski, MD, PhD, Igor Espinoza-Delgado, MD, Judith E. Karp, MD

Blood (2011) 118 (21): 1755.

https://doi.org/10.1182/blood.V118.21.1755.1755

Published: 2011

Journal Articles

Defining the Topography of Deletion 5q Using SNP-A Identifies Patients with More Aggressive Disease and Correlates with Additional Lesions

Andres Jerez, MD, Anna M Jankowska, PhD, Hideki Makishima, MD, Lukasz P Gondek, MD, Ramon V Tiu, MD, Christine L O‘Keefe, PhD, Azim M Mohamedali, PhD, Denise Batista, PhD, Michael A McDevitt, MD, PhD, Mikkael A Sekeres, MD, Ghulam J. Mufti, MD, Jaroslaw P Maciejewski, MD, PhD

Blood (2011) 118 (21): 2795.

https://doi.org/10.1182/blood.V118.21.2795.2795

Published: 2011

Journal Articles

Consequences of UTX Dysfunction in Myelodysplastic Syndrome

Anna M Jankowska, PhD, Hadrian Szpurka, PhD, Venugopalan Cheriyath, PhD, Kwok Peng Ng, PhD, Zhenbo Hu, MD, Michael A McDevitt, MD, Yogen Saunthararajah, MD, Jaroslaw P. Maciejewski, MD, PhD

Blood (2011) 118 (21): 2427.

https://doi.org/10.1182/blood.V118.21.2427.2427

Published: 2011

NARROW

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

The JAK2 V617F Stem Cell Burden Is Mosaic, Dynamic and Correlates with Clinical Disease Burden in the MPN: An Exploitable Target

Dynamics of Mutations in Patients with ET Treated with Imetelstat

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Essential Thrombocytosis: Redefinition in the Genomic Era

Epigenetic Silencing of BRCA1 Is Linked to Homologous Recombination Repair Defects and Elevated Mir-155 Expression in Myeloid Neoplasms

Monitoring of Calr Allele Burden in Patients with Essential Thrombocythemia Treated with Imetelstat, a Telomerase Inhibitor, Reveals Rapid and Substantial Molecular Responses

Single Cell Analysis Of JAK2 V617F Positive MPN Stem/Progenitor Cells In Chronic Phase and Leukemic Transformation

Burst-Forming Unit-Erythroid Assays (BFU-E) Can Help Distinguish Cellular Bone Marrow Failure Disorders

Polycythemia Vera: Redefinition in the Genomic Era

Somatic Mutations in Schinzel-Giedion Syndrome Gene SETBP1 Determine Progression in Myeloid Malignancies

Pathway Analysis of Molecular Mutations Can Modify Morphologic, Cytogenetic and Prognostic Risk Stratification Schemes in Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN), and Secondary Acute Myeloid Leukemia (AML)

Novel Recurrent Mutations in the Ras -Like GTP-Binding Gene Rit1 in Myeloid Malignancies

Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Final Results From a Phase II Trial of Triapine® Plus Fludarabine for Adults with Aggressive Myeloproliferative Disorders

Defining the Topography of Deletion 5q Using SNP-A Identifies Patients with More Aggressive Disease and Correlates with Additional Lesions

Consequences of UTX Dysfunction in Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only